Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022–August 2023

IF 4.3 4区 医学 Q1 INFECTIOUS DISEASES Influenza and Other Respiratory Viruses Pub Date : 2024-11-04 DOI:10.1111/irv.70027
Jennifer DeCuir, Diya Surie, Yuwei Zhu, Adam S. Lauring, Manjusha Gaglani, Tresa McNeal, Shekhar Ghamande, Ithan D. Peltan, Samuel M. Brown, Adit A. Ginde, Aimee Steinwand, Nicholas M. Mohr, Kevin W. Gibbs, David N. Hager, Harith Ali, Anne Frosch, Michelle N. Gong, Amira Mohamed, Nicholas J. Johnson, Vasisht Srinivasan, Jay S. Steingrub, Akram Khan, Laurence W. Busse, Abhijit Duggal, Jennifer G. Wilson, Nida Qadir, Steven Y. Chang, Christopher Mallow, Jennie H. Kwon, Matthew C. Exline, Nathan I. Shapiro, Cristie Columbus, Ivana A. Vaughn, Mayur Ramesh, Basmah Safdar, Jarrod M. Mosier, Jonathan D. Casey, H. Keipp Talbot, Todd W. Rice, Natasha Halasa, James D. Chappell, Carlos G. Grijalva, Adrienne Baughman, Kelsey N. Womack, Jillian P. Rhoads, Sydney A. Swan, Cassandra Johnson, Nathaniel Lewis, Sascha Ellington, Fatimah S. Dawood, Meredith McMorrow, Wesley H. Self, for the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network
{"title":"Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022–August 2023","authors":"Jennifer DeCuir,&nbsp;Diya Surie,&nbsp;Yuwei Zhu,&nbsp;Adam S. Lauring,&nbsp;Manjusha Gaglani,&nbsp;Tresa McNeal,&nbsp;Shekhar Ghamande,&nbsp;Ithan D. Peltan,&nbsp;Samuel M. Brown,&nbsp;Adit A. Ginde,&nbsp;Aimee Steinwand,&nbsp;Nicholas M. Mohr,&nbsp;Kevin W. Gibbs,&nbsp;David N. Hager,&nbsp;Harith Ali,&nbsp;Anne Frosch,&nbsp;Michelle N. Gong,&nbsp;Amira Mohamed,&nbsp;Nicholas J. Johnson,&nbsp;Vasisht Srinivasan,&nbsp;Jay S. Steingrub,&nbsp;Akram Khan,&nbsp;Laurence W. Busse,&nbsp;Abhijit Duggal,&nbsp;Jennifer G. Wilson,&nbsp;Nida Qadir,&nbsp;Steven Y. Chang,&nbsp;Christopher Mallow,&nbsp;Jennie H. Kwon,&nbsp;Matthew C. Exline,&nbsp;Nathan I. Shapiro,&nbsp;Cristie Columbus,&nbsp;Ivana A. Vaughn,&nbsp;Mayur Ramesh,&nbsp;Basmah Safdar,&nbsp;Jarrod M. Mosier,&nbsp;Jonathan D. Casey,&nbsp;H. Keipp Talbot,&nbsp;Todd W. Rice,&nbsp;Natasha Halasa,&nbsp;James D. Chappell,&nbsp;Carlos G. Grijalva,&nbsp;Adrienne Baughman,&nbsp;Kelsey N. Womack,&nbsp;Jillian P. Rhoads,&nbsp;Sydney A. Swan,&nbsp;Cassandra Johnson,&nbsp;Nathaniel Lewis,&nbsp;Sascha Ellington,&nbsp;Fatimah S. Dawood,&nbsp;Meredith McMorrow,&nbsp;Wesley H. Self,&nbsp;for the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network","doi":"10.1111/irv.70027","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Assessments of COVID-19 vaccine effectiveness are needed to monitor the protection provided by updated vaccines against severe COVID-19. We evaluated the effectiveness of original monovalent and bivalent (ancestral strain and Omicron BA.4/5) COVID-19 vaccination against COVID-19-associated hospitalization and severe in-hospital outcomes.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>During September 8, 2022 to August 31, 2023, adults aged ≥ 18 years hospitalized with COVID-19-like illness were enrolled at 26 hospitals in 20 US states. Using a test-negative case–control design, we estimated vaccine effectiveness (VE) with multivariable logistic regression adjusted for age, sex, race/ethnicity, admission date, and geographic region.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Among 7028 patients, 2924 (41.6%) were COVID-19 case patients, and 4104 (58.4%) were control patients. Compared to unvaccinated patients, absolute VE against COVID-19-associated hospitalization was 6% (−7%–17%) for original monovalent doses only (median time since last dose [IQR] = 421 days [304–571]), 52% (39%–61%) for a bivalent dose received 7–89 days earlier, and 13% (−10%–31%) for a bivalent dose received 90–179 days earlier. Absolute VE against COVID-19-associated invasive mechanical ventilation or death was 51% (34%–63%) for original monovalent doses only, 61% (35%–77%) for a bivalent dose received 7–89 days earlier, and 50% (11%–71%) for a bivalent dose received 90–179 days earlier.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Bivalent vaccination provided protection against COVID-19-associated hospitalization and severe in-hospital outcomes within 3 months of receipt, followed by a decline in protection to a level similar to that remaining from previous original monovalent vaccination by 3–6 months. These results underscore the benefit of remaining up to date with recommended COVID-19 vaccines.</p>\n </section>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.70027","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70027","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Assessments of COVID-19 vaccine effectiveness are needed to monitor the protection provided by updated vaccines against severe COVID-19. We evaluated the effectiveness of original monovalent and bivalent (ancestral strain and Omicron BA.4/5) COVID-19 vaccination against COVID-19-associated hospitalization and severe in-hospital outcomes.

Methods

During September 8, 2022 to August 31, 2023, adults aged ≥ 18 years hospitalized with COVID-19-like illness were enrolled at 26 hospitals in 20 US states. Using a test-negative case–control design, we estimated vaccine effectiveness (VE) with multivariable logistic regression adjusted for age, sex, race/ethnicity, admission date, and geographic region.

Results

Among 7028 patients, 2924 (41.6%) were COVID-19 case patients, and 4104 (58.4%) were control patients. Compared to unvaccinated patients, absolute VE against COVID-19-associated hospitalization was 6% (−7%–17%) for original monovalent doses only (median time since last dose [IQR] = 421 days [304–571]), 52% (39%–61%) for a bivalent dose received 7–89 days earlier, and 13% (−10%–31%) for a bivalent dose received 90–179 days earlier. Absolute VE against COVID-19-associated invasive mechanical ventilation or death was 51% (34%–63%) for original monovalent doses only, 61% (35%–77%) for a bivalent dose received 7–89 days earlier, and 50% (11%–71%) for a bivalent dose received 90–179 days earlier.

Conclusion

Bivalent vaccination provided protection against COVID-19-associated hospitalization and severe in-hospital outcomes within 3 months of receipt, followed by a decline in protection to a level similar to that remaining from previous original monovalent vaccination by 3–6 months. These results underscore the benefit of remaining up to date with recommended COVID-19 vaccines.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
2022 年 9 月至 2023 年 8 月期间,原始单价和二价 COVID-19 疫苗对美国成人 COVID-19 相关住院和严重住院后果的预防效果。
背景:需要对 COVID-19 疫苗的有效性进行评估,以监测更新疫苗对重症 COVID-19 所提供的保护。我们评估了原始单价和二价(祖先株和 Omicron BA.4/5)COVID-19 疫苗接种对与 COVID-19 相关的住院和严重住院后果的有效性:在 2022 年 9 月 8 日至 2023 年 8 月 31 日期间,美国 20 个州的 26 家医院对因 COVID-19 类疾病住院的年龄≥ 18 岁的成人进行了登记。我们采用试验阴性病例对照设计,并根据年龄、性别、种族/民族、入院日期和地理区域进行调整,通过多变量逻辑回归估算疫苗有效性(VE):在 7028 名患者中,有 2924 人(41.6%)为 COVID-19 病例患者,4104 人(58.4%)为对照组患者。与未接种疫苗的患者相比,仅接种原始单价疫苗(最后一次接种后的中位时间[IQR] = 421天[304-571])的患者预防COVID-19相关住院的绝对VE为6%(-7%-17%),提前7-89天接种二价疫苗的患者预防COVID-19相关住院的绝对VE为52%(39%-61%),提前90-179天接种二价疫苗的患者预防COVID-19相关住院的绝对VE为13%(-10%-31%)。对于与COVID-19相关的侵入性机械通气或死亡,仅接种原始单价疫苗的绝对VE为51%(34%-63%),提前7-89天接种二价疫苗的绝对VE为61%(35%-77%),提前90-179天接种二价疫苗的绝对VE为50%(11%-71%):结论:二价疫苗接种可在接种后 3 个月内预防 COVID-19 引起的住院和严重住院后果,随后保护作用会下降,在 3-6 个月内降至与之前接种单价疫苗时的保护作用相似的水平。这些结果凸显了及时接种推荐的 COVID-19 疫苗的益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
7.20
自引率
4.50%
发文量
120
审稿时长
6-12 weeks
期刊介绍: Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.
期刊最新文献
Measures of Population Immunity Can Predict the Dominant Clade of Influenza A (H3N2) in the 2017–2018 Season and Reveal Age-Associated Differences in Susceptibility and Antibody-Binding Specificity Effectiveness of Original Monovalent and Bivalent COVID-19 Vaccines Against COVID-19-Associated Hospitalization and Severe In-Hospital Outcomes Among Adults in the United States, September 2022–August 2023 Expansion of Laboratory Capacity in the Eastern Mediterranean Region During the COVID-19 Pandemic: Lessons Learned and Future Strategies for Sustainability Inno4Vac Workshop Report Part 1: Controlled Human Influenza Virus Infection Model (CHIVIM) Strain Selection and Immune Assays for CHIVIM Studies, November 2021, MHRA, UK Real-World Assessment of Economic and Clinical Outcomes in Thai Patients With Respiratory Syncytial Virus Infection Across Age Groups: A Retrospective Cohort Analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1